DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc [https://c212.net/c/link/?t=0&l=en&o=4332694-1&h=2276053630&u=http%3A%2F%2Fwww.alkermes.com%2F&a=Alkermes+plc] announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43(rd) Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com [https://c212.net/c/link/?t=0&l=en&o=4332694-1&h=2619123792&u=http%3A%2F%2Fwww.alkermes.com%2F&a=www.alkermes.com] and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com [https://c212.net/c/link/?t=0&l=en&o=4332694-1&h=2619123792&u=http%3A%2F%2Fwww.alkermes.com%2F&a=www.alkermes.com].
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg [https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg]
View original content:https://www.prnewswire.co.uk/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341500.html [https://www.prnewswire.co.uk/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341500.html]
Photo: https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg Alkermes plc
